Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors

NCT04242199 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

182

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor
MSI-H/dMMR Tumors
Cutaneous Squamous Cell Carcinoma
Urothelial Carcinoma
Cervical Cancer
HepatoCellular Carcinoma
Esophageal Squamous Cell Carcinoma
Merkel Cell Carcinoma
Small-cell Lung Cancer
Mesothelioma
PD-L1 Amplified Tumor (9p24.1)
Nasopharyngeal Carcinoma

Interventions

DRUG: INCB099280

Sponsor

Incyte Corporation